الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 104 |  |  |
| | | from | 104 | | |
Abstract
Low back pain has become a major problem and leading cause for depression and disability. Sacroiliac pain is a common source of low back pain and its diagnosis and management is a challenging issue. Sacroiliac joint injection is one of the promising interventional management.
This study evaluated the effect of adding dexmedetomidine as an adjuvant to steroid injection versus steroid alone in chronic low back pain caused by sacroiliac joint arthritis.
Sixty Patients of both sex, American Society of Anesthesiologists physical status classification (ASA) grade 1 and 2, between the ages of 18-70 years, BMI less than 30 kg/m2, after diagnosis of Sacroiliac joint dysfunction and failure of conservative management were randomly allocated into two groups by using the sealed envelope method (n=30)
group (1): patients will receive SI injection with 2ml of long-acting corticosteroid (14 mg) Betamethasone and 0.5 ml of normal saline.
group (2): patients will receive SI injection with 2ml of long-acting corticosteroid (14 mg) Betamethasone and 0.5 ml Dexmedetomidine 50 mcg.
Patient was observed for vital signs, pain and possible side effects in the recovery room for 4 hours then discharged. The patient’s pain intensity using Numerical Rating Scale (0 no pain, 1-3 mild pain, 4-6 moderate pain, 7-10 severe pain), or functional improvement using Oswestry Disability Index and Functional Rating Scale and complications will followed up at 2 weeks, 1 month and 3 months. Short assessment of patient satisfaction will be assessed 2 weeks after injection.
The results revealed that addition of dexmedetomidine to steroids in sacroiliac joint injection is of low value. There was no statistically significant difference between steroid group and dexmedetomidine group regarding the changes in the NRS, ODI and FRI scores at two weeks, one month, and three months after injection.